Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18568866 | 0.82 | GAA (0.68) | ALDH1A1GAAL3MBTL1HPGDKDM4E | |
| SCHEMBL8273732 | 0.79 | ALDH1A1 (0.50) | TOP1ALDH1A1GAAL3MBTL1HPGD | |
| SCHEMBL8274847 | 0.78 | MEN1 (0.55) | ALDH1A1GAAL3MBTL1HTTTSHR | |
| SCHEMBL18569320 | 0.78 | GAA (0.56) | ALDH1A1GAAL3MBTL1HPGDKDM4E | |
| Ubisindine SCHEMBL191543 | 0.76 | TSHR (0.62) | ALDH1A1POLBGAAL3MBTL1HPGD | |
| SCHEMBL18569319 | 0.73 | GAA (0.44) | ALDH1A1GAAL3MBTL1HPGDTSHR | |
| Diethylamine SCHEMBL9667757 | 0.72 | GAA (0.49) | TOP1GAAL3MBTL1TSHRFFAR1 | |
| SCHEMBL3029406 | 0.72 | MAPT (0.50) | ALDH1A1POLBGAAL3MBTL1HTT | |
| SCHEMBL3029407 | 0.72 | MAPT (0.50) | ALDH1A1POLBGAAL3MBTL1HTT | |
| SCHEMBL8272076 | 0.72 | TP53 (0.59) | ALDH1A1GAAHTTTSHRMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149716-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149716-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | PDE4A, PDE4B, PDE4C | TOP1 461/4885ALDH1A1 1159/4885POLB 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.